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Dipolar cycloadditionsAn efﬁcient synthetic access to two amino-oxazoline compound libraries was developed employing the
branching cascades approach. A common precursor, that is, chromonylidene b-ketoester was transformed
into two different ring-systems, that is, the pyridine and the benzopyrane substituted hydroxyphenones.
In further two steps, the ketone moiety in two ring-systems was transformed into an amino-oxazoline
ring. The functional groups on the two amino-oxazoline scaffolds were exploited further to generate, a
compound collection of ca. 600 amino-oxazolines which are being exposed to various biological screen-
ings within the European Lead Factory consortium.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Discovery of small bioactive molecules as the potential drug
candidates largely depends on the structural diversity in a com-
pound collection, that is, exposed to biological screenings.1 Over
the years, pharmaceutical industry has witnessed a continuous fall
in the number of hit and lead structures emanating from their
compound collections.2 It was realized that organic synthesis has
in fact, focused only on a small percentage of the chemical space,
as far as structural diversity in synthetic small molecules is con-
cerned.3 Therefore, a vast unknown chemical space remains
untapped for its potential to deliver biologically interesting small
molecules. To identify novel chemical probes and drug candidates
therefore requires the compound libraries rich in structural diver-
sity which in turn is determined by the number of different chemo-
types that a library represents.4 Consequently, the synthetic
designs aiming at divergent access to structurally distinct scaffolds
and libraries are highly desired.5
The European Lead Factory (ELF) is a unique public–private
platform where academics and SMEs (small and medium enter-
prises) collaborate extensively in drug-discovery programs on the
promising biology targets or the chemistry scaffolds. While seven
pharmaceutical companies have contributed around 300,000 opti-
mized industrial research compounds, the SMEs and academicinstitutions target a further 200,000 novel compounds in the next
three years, thereby creating a Joint European Compound Collec-
tion of up to half a million compounds.6
Recently, we introduced the branching cascades7 as a scaffold
diversity synthesis approach wherein different cascade or domino
reactions on a common precursor provide distinct scaffolds that
can be used to generate a skeletally rich compound collection
(Fig. 1).8 Discovery of the spiro-amino-oxazolines9 as an interest-
ing class of molecules that can be used for the treatment of Alzhei-
mer’s disease and other neurodegenerative disorders inspired us to
target novel amino-oxazoline scaffolds for building compound
library for the Joint European Compound Collection.6 To this end,
we envisioned to employ the branching cascades strategy to syn-
thesize different scaffolds and subsequently generate focused
libraries around these scaffolds (Fig. 1).
In order to gain access to structurally novel and highly substi-
tuted sets of the amino-oxazolines with drug like molecular prop-
erties10 (e.g., Mol. wt. 6 500 and cLogP in range 1 to 4.0) for
different screening endeavors of ELF consortium, a cascade reac-
tion based strategy as depicted in Scheme 1 was designed.11 Thus,
easily accessible chromonylidene b-ketoesters (A) when treated
with different reagents, follow different cascade reaction pathways
and provide either the pyridine or the benzopyrane substituted
hydroxyphenones B or C, respectively, (Scheme 1a). These interme-
diates can be transformed into two different sets of novel amino-
oxazolines D or E. Transformation of ketone B or C into the desired
amino-oxazolines requires the Wittig oleﬁnation of ketone
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Figure 1. The concept of branching cascades to deliver scaffold diversity.
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Scheme 2. Synthesis of pyridyl-aryl amino-oxazoline scaffold (D).
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Scheme 3. Synthesis of pyridyl-aryl amino-oxazoline scaffold (D).
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Scheme 1. Synthesis design for two amino-oxazoline compound collections. (a)
Branching cascades on A yield substrates for two amino-oxazoline libraries. (b) Key
steps leading to amino-oxazoline ring-system.
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treatment with aq ammonia would undergo cyclization reaction
to yield the amino-oxazolines D or E (Scheme 1b).9a
An obvious advantage of this strategy is that the synthesis opti-
mization of the scaffolds, which is the most time consuming and
synthetically challenging part of building a compound collection,
would be easily streamlined because of the common reactions
employed in the synthesis designs of two scaffolds (Scheme 1b).
2. Results and discussion
2.1. Synthesis optimization of the pyridyl-aryl amino-oxazoline
scaffold (D)
To test the viability of the amino-oxazoline synthesis by utiliz-
ing our reported protocol for the synthesis of pyridine substituted
hydroxyphenones (4a–c), substrate b-ketoesters (3a–c) were pre-
pared from the corresponding substituted chromone-3-carbalde-
hydes (1a–c) and ethyl acetoacetate (2) in good yield.11 On
treatment with ammonium ﬂuoride in methanol under reﬂux con-
ditions, 3a–c undergo a cascade reaction sequence to afford the
corresponding pyridine substituted hydroxyphenones 4a–c in
good to excellent yields (Scheme 2).11 The oleﬁnation of tert-
butyldimethylsilyl (TBS) protected phenol 5, under Wittig reaction
conditions gave the desired product 6, albeit in poor yield.12 There-
fore, we resorted to Peterson oleﬁnation using trimethylsilyl
methyl lithium that provided the desired oleﬁn 6, however, along
with major amount of desilylated oleﬁn 7 (Scheme 3a).13
To avoid the silyl deprotection during Peterson oleﬁnation
(Scheme 3a), the hydroxyl group in phenolic ketones 4 wasprotected as p-methoxybenzyl (PMB) ether in very good yield by
treating with 4-methoxybenzyl chloride in the presence of potassi-
um carbonate.14 The ketones 8a–c were converted into the corre-
sponding oleﬁn 9a–c in good yields by using trimethylsilyl
methyl lithium (Scheme 3b). Finally, treatment of oleﬁn 9a–c with
iodine and silver isocyanate and followed by aq ammonia provided
the expected amino-oxazoline derivatives 10a–c in moderate
yields (Scheme 3a).
We planned to modify the phenolic hydroxyl moiety in amino-
oxazoline scaffold, for instance by alkylation, before a combinato-
rial synthesis step that utilizes the carboxylic acid moiety on the
pyridine ring is executed. Thus, the p-methoxybenzyl group was
deprotected smoothly using triﬂuoroacetic acid (TFA) in CH2Cl2
affording the corresponding phenolic derivative 11 in excellent
yield (90%).15 The hydroxyl group was alkylated using methyl
iodide in the presence of potassium carbonate. Unfortunately we
observed formation of a mixture of O- and N-alkylated products
(12/12a; 1.5:1) in low yield even at room temperature.16 In addi-
tion the reaction was incomplete even after prolonged reaction
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Scheme 4. Phenolic methylation of the pyridyl-aryl amino-oxazoline (11).
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Scheme 6. Production of pyridyl-aryl amino-oxazoline library.
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group before the cyclization step that generates amino-oxazoline
ring in order to avoid the PMB protection-deprotection steps.
Thus, hydroxyl group in 4a was alkylated using methyl iodide
and potassium carbonate. Oleﬁnation of ketone 13 under opti-
mized condition of trimethylsilyl methyl lithium afforded the cor-
responding oleﬁn 14 in good yield. Finally, treatment of the oleﬁn
14 with iodine and silver isocyanate followed by aq ammonia
afforded the expected amino-oxazoline derivative 12 in good yield
(Scheme 5).
Saponiﬁcation of the ester group in 12 to the corresponding car-
boxylic acid went smoothly and in quantitative yield. The car-
boxylic acid moiety was used as a combinatorial handle for
derivatization of the amino-oxazoline scaffold to build a compound
collection. To optimize this synthetic step, carboxylic acid was
coupled with diethyl amine in the presence of 1-[bis(dimethy-
lamino)methylene]-1H-1,2,3-triazolo[4,5-b]-pyridinium 3-oxid
hexaﬂuorophosphate (HATU) and diisopropylethyl amine provid-
ing the corresponding amide 15 in good yield (Scheme 5).
2.1.1. Production of the pyridyl-aryl amino-oxazoline library
To build a compound library, three points of diversity in the
pyridyl-aryl amino-oxazoline scaffold was exploited (Scheme 6).
A matrix of 3  3  48 chromone-3-carbaldehydes, alkyl iodides
and amines was selected to ensure at least 80% of the ﬁnal com-
pounds have ‘lead-like’ properties, here deﬁned as molecular
weight 6 400 Da or calculated logP 6 4. These physicochemical
constraints, commercial availability and cost considerations
prompted us to select monoatomic substituents (H, Me, F) at posi-MeO O
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Scheme 5. Synthesis and functionalization of pyridyl-aryl amino-oxazoline scaffold
(12).tion 6 of the starting chromone-3-carbaldehydes and small alkyl
iodides (methyl, ethyl and propyl) to allow for more ﬂexibility in
the choice of amine, as ﬁnal diversity element.
As shown in Scheme 6, synthesis proved to be adequately repro-
ducible across different substrates. The yields obtained from Peter-
son oleﬁnation and the silver isocyanate-mediated cyclization
reactions however varied with substrates and were generally on
the lower side at higher scale (cf. Schemes 5 and 6). In the case
of Peterson oleﬁnation, this could be attributed to the partial
hydrolysis of the ethyl ester functionality and that was observed
for all substrates (13) under the described conditions. Amide for-
mation in the last step using HATU as a carboxylic acid activating
agent did not prove to be robust enough for a wide range of sub-
strates envisioned. Initial tests provided the products in poor yields
(<50%) when executed in a parallel fashion using 15 mL reaction
tubes in a 24 position Mettler Toledo Miniblock using a pilot set
of 24 diverse amines. Amide coupling conditions were then opti-
mized employing ethyl-(N0,N0-dimethylamino)propylcarbodiimide
hydrochloride (EDCHCl) and 1-hydroxybenzotriazole (HOBt) in
the presence of diisopropylethylamine (DIPEA) in dimethylfor-
mamide (DMF) (Scheme 6). After HPLC/MS-based analysis and
puriﬁcation, this improved synthetic protocol yielded a total 346
compounds (out of total 432 reactions performed) of sufﬁcient
quantity (>5 lmol; 3–18 mg) and purity (LC–MS >85%), translating
to an overall 81% success rate.
2.2. Synthesis optimization of the benzopyrane-aryl amino-
oxazoline scaffold (E)
To generate chromonylidene b-ketoesters (19), the substrates
for the reagent controlled cascade synthesis of benzopyrane substi-
tuted hydroxyphenones (20), 3-bromo-1-propanol was protected
as TBS ether and followed by alkylation with methyl acetoacetate
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Scheme 7. Synthesis of the ketones (20), the substrates for the benzopyrane-aryl
amino-oxazoline scaffold.
A. Murali et al. / Bioorg. Med. Chem. 23 (2015) 2656–2665 2659affording b-ketoester (18) in moderate yield (Scheme 7). Conden-
sation reaction of chromone 3-carbaldehydes and b-ketoester
(18) afforded the desired chromonylidene b-ketoesters 19a–c in
good yields. Treatment of the chromonylidene b-ketoesters 19a–c
with pyridinium p-toluene sulfonate (PPTS) under reﬂux condi-
tions in methanol afforded the benzopyrane substituted hydrox-
yphenones 20a–c in moderate to good yields (Scheme 7).11
Hydroxyl group in the benzopyrane 20was protected as methyl
ether using methyl iodide and potassium carbonate. Peterson ole-
ﬁnation of the ketone under previously optimized conditions
afforded the corresponding oleﬁns 22a and 22b in good yields.O
R1
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Scheme 8. Synthesis of benzopyraneThe latter oleﬁns on treatment with iodine in the presence of silver
isocyanate and aq ammonia provided the desired amino-oxazoline
23a and 23b in moderate yield (Scheme 8a). The ester group of the
key intermediate (23b) was hydrolyzed to obtain the carboxylic
acid in quantitative yield. The carboxylic acid moiety was used as
a combinatorial handle for the synthesis of various amides. For
instance, carboxylic acid obtained from 23b was coupled with
n-propyl amine in the presence of HATU and Hünig’s base to give
the corresponding amide 24 in moderate yield (Scheme 8b).
2.2.1. Production of the benzopyrane-aryl amino-oxazoline
library
In analogy to the synthesis of pyridyl-aryl amino-oxazoline-
based library, a combination of 3  3  48 chromone-3-carbalde-
hydes, alkyl iodides and amines was selected to enumerate the
ﬁnal library of benzopyrane-aryl amino-oxazoline derivatives, as
summarized in Scheme 9. The moderate overall yield of the syn-
thesis sequence leading to benzopyrane-aryl amino-oxazoline
scaffold and the necessary combinatorial amide synthesis step at
a later stage called for the preparation of large amounts of the
TBS-protected alcohol precursor 17 (ca. 340 g) to afford sufﬁcient
quantity of the core-scaffold. In this synthesis sequence, we there-
fore preferred a Wittig reaction in lieu of Peterson oleﬁnation. This
proved to be better yielding, required shorter reaction time (7 vs
18 h) and afforded a simpliﬁed reaction work-up. Lower costs
and better stability of the Wittig reagents (methyltriphenyl phos-
phonium bromide and potassium tert-butoxide) offered additional
advantages. Interestingly, cyclization reaction yielding amino-
oxazoline worked even better at higher scale (cf. Schemes 8 and 9).
Final products, that is, amides (24) were synthesized from the
lithium salts of carboxylic acids obtained from 23a–g, following
the previously described EDCHCl/HOBt amidiﬁcation protocol
(Scheme 9). This resulted in a total of 269 derivatives out of the
336 executed reactions (80% success rate). The ﬁnal compounds
were obtained in the range of 5–22 mg that was enough to obtain
analytical data for representative set of compounds as well as toCO2Me
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Scheme 9. Production of the benzopyrane-aryl amino-oxazoline library.
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pean Compound Collection.
3. Conclusions
A concise access to two diverse amino-oxazoline libraries was
developed utilizing branching cascades approach. Chromonyli-
dene-b-ketoesters were thus transformed into two distinct
scaffolds, that is, hydroxyphenone supporting pyridines and ben-
zopyranes. Both the scaffolds were transformed into the corre-
sponding amino-oxazoline compound collections which have
been submitted to ELF consortium and are being exposed to var-
ious HTS campaigns to identify promising drug candidates.
4. Experimental section
4.1. General information
Chemicals and solvents were obtained from commercial suppli-
ers and were used without further puriﬁcation. All dry reactions
were performed under argon atmosphere using commercial dry
solvents. Protecting groups, solvents and reagents are abbreviated
as follows: ammonium chloride (NH4Cl), tetrahydrofuran (THF),
ethyl acetate (EtOAc), tert-butyl methyl ether (TBME), diethyl ether
(Et2O) and cyclohexane (CyH). Flash column chromatography was
performed on a silica column using 230400 mesh silica gel or
Grace Reveleris X2 ﬂash chromatography system using silica gel
packed Macherey Nagel Chromabond Flash BT cartridges (60 Å,
45 lm) and Grace Reveleris ﬂash Cartridges (60 Å, 40 lm). Thin-
layer chromatography was performed on Macherey Nagel pre-
coated TLC aluminum sheets with silica gel 60 UV254 (5–17 lm).
Compound visualization was effected with a 5% solution of phos-
phomolybdic acid in ethanol, 0.5% solution of ninhydrin in ethanol,
UV lamp or iodine and KMnO4 solution. 1H NMR spectra wererecorded at room temperature on a Bruker Avance spectrometer
operating at 300 MHz and 400 MHz. Chemical shifts are given in
ppm (d) from tetramethylsilane as an internal standard or residual
solvent peak. Signiﬁcant 1H NMR data are tabulated in the follow-
ing order: multiplicity (s, singlet; d, doublet; t, triplet; q, quartet;
m, multiplet; br, broad), coupling constant(s) in hertz, number of
protons. Analytical, preparative HPLC and Electron Spray Ionization
condition (ESI) mass spectra were performed on an Agilent uHPLC
(1290 Inﬁnity) and an Agilent Prep-HPLC (1260 Inﬁnity) both
equipped with a Diode Array Detector and a Quadrupole MSD
using mixture gradients of Formic acid/water/acetonitrile as sys-
tem solvent. High-resolution electrospray ionization mass spectra
(ESI-FTMS) were recorded on a Thermo LTQ Orbitrap (high-resolu-
tion mass spectrometer from Thermo Electron) coupled to an ‘Ac-
cela’ HPLC system supplied with a ‘Hypersil GOLD’ column
(Thermo Electron).
5. Experimental section
5.1. Ethyl 3-oxo-2-((4-oxo-4H-chromen-3-yl)methylene)
butanoate (3a)
To a mixture of 3-formyl-chromone (20.0 g, 112.54 mmol),
ethyl acetoacetate (17.9 g, 112.54 mmol), sodium acetate (9.4 g,
112.54 mmol) was added acetic anhydride (100 mL) and the reac-
tion mixture was heated and stirred at 125 C for 4 h. After com-
plete consumption of 3-formyl chromone, the reaction mixture
was cooled to room temperature (rt) and acetic anhydride was
removed under reduced pressure. The residue was re-dissolved
in ethyl acetate (250 mL), washed with water (2  50 mL), brine
solution (1  50 mL), dried over anhydrous Na2SO4 and concen-
trated to afford the crude product. The crude mixture was puriﬁed
by ﬂash column chromatography on silica gel (230400 mesh)
using 2–5% EtOAc/CyH to afford pure compound 3a (21.6 g, 67%)
as a pale yellow solid (cis/trans isomer; 1:1). 1H NMR (400 MHz,
CDCl3): d 8.33 (s, 1H), 8.28 (s, 1H), 8.23 (td, J = 8.7, 1.2 Hz, 2H),
7.70 (td, J = 8.9, 1.7 Hz, 2H), 7.64 (s, 1H), 7.56 (s, 1H), 7.52–7.38
(m, 4H), 4.37–4.26 (m, J = 7.1 Hz, 4H), 2.48 (s, 3H), 2.45 (s, 3H),
1.34 (t, J = 7.1 Hz, 3H), 1.29 (t, J = 7.2 Hz, 3H). 13C NMR (101 MHz,
CDCl3): d 195.3, 175.4, 167.1, 164.6, 157.5, 156.7, 156.1, 156.1,
136.2, 134.6, 134.5, 132.1, 131.8, 126.6, 126.6, 126.3, 126.1,
123.9, 123.9, 119.3, 118.5, 118.4, 62.0, 61.9, 26.9, 14.4, 14.2.
HPLC-MS (ESI) m/z calcd for C16H15O5 [M+H]+: 287.09, found:
286.80. TLC Rf = 0.8 (30% EtOAc/CyH).
5.2. Ethyl 5-(2-hydroxybenzoyl)-2-methylnicotinate (4a)
To a solution of 3a (10.0 g, 34.93 mmol) in MeOH (100 mL), was
added NH4F (12.93 g, 349.3 mmol) and reﬂuxed at 80 C for 6 h.
After the completion of reaction (tlc), it was cooled to rt and
methanol was removed under reduced pressure. The residue was
re-dissolved in ethyl acetate (150 mL) washed with water
(2  25 mL), brine solution (1  25 mL) and dried over anhydrous
Na2SO4. Ethyl acetate was evaporated under reduced pressure to
give crude 3a that was then puriﬁed by ﬂash column chromatogra-
phy on silica gel (230400 mesh) using EtOAc/CyH 5–10% as a gra-
dient to afford pure compound 4a (8.2 g, 83%) as a white solid. 1H
NMR (400 MHz, CDCl3): d 11.74 (s, 1H), 8.87 (d, J = 2.2 Hz, 1H), 8.51
(d, J = 2.2 Hz, 1H), 7.70–7.42 (m, 2H), 7.07 (dt, J = 8.5, 0.9 Hz, 1H),
6.91 (ddd, J = 8.1, 7.2, 1.1 Hz, 1H), 4.50–4.26 (m, 2H), 2.92 (d,
J = 19.4 Hz, 3H), 1.40 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3):
d 198.3, 165.6, 163.5, 163.2, 151.1, 139.5, 137.4, 133.0, 131.5,
126.0, 119.4, 119.1, 119.0, 62.1, 25.0, 14.4. HPLC-MS (ESI)m/z calcd
for C16H16NO4 [M+H]+: 286.11, found: 286.09. TLC Rf = 0.6 (30%
EtOAc/CyH).
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cotinate (8a)
To a heterogeneous solution of 4a (6.5 g, 22.1 mmol) and K2CO3
(9.16 g, 66.29 mmol) in acetone (57 mL), was added 4-methoxy-
benzyl chloride (4.28 g, 26.52 mmol) dropwise and it was reﬂuxed
for 18 h. Upon completion of reaction (tlc), the mixture was cooled
to rt and ﬁltered on a celite pad, washed a couple of times with
ethyl acetate (2  20 mL). The solvent was evaporated under
reduced pressure to give the crude product mixture that was puri-
ﬁed by ﬂash column chromatography on silica gel (230–400 mesh)
using EtOAc/CyH (5–10%) as a gradient to afford pure compound
8a (8.1 g, 90%) as a pale yellow viscous liquid.1H NMR (400 MHz,
CDCl3): d 8.81–8.79 (m, 1H), 8.49–8.46 (m, 1H), 7.54–7.45 (m,
2H), 7.08 (td, J = 7.5, 0.9 Hz, 1H), 7.02 (d, J = 8.3 Hz, 1H), 6.90–
6.86 (m, 2H), 6.71–6.67 (m, 2H), 4.86 (s, 2H), 4.35 (q, J = 7.1 Hz,
2H), 3.73 (s, 3H), 2.82 (s, 3H), 1.36 (t, J = 7.1 Hz, 3H). 13C NMR
(101 MHz, CDCl3): d 194.3, 166.1, 163.3, 159.5, 157.2, 152.4,
138.9, 133.7, 132.0, 130.7, 128.9, 128.7, 127.9, 125.6, 121.5,
113.9, 113.1, 70.6, 61.8, 55.4, 25.2, 14.3. HPLC-MS (ESI) m/z calcd
for C24H24NO5 [M+H]+: 406.17, found: 406.09. TLC Rf = 0.5 (30%
EtOAc/CyH).
5.4. Ethyl 5-(1-(2-((4-methoxybenzyl)oxy)phenyl)vinyl)-
2-methyl-nicotinate (9a)
To a solution of ketone 8a (5.0 g, 12.33 mmol) in THF (60.0 mL),
was added trimethylsilyl methyl lithium (1.74 g, 18.50 mmol;
1.0 M solution in THF) dropwise at 78 C over a period of
15 min. The resulting solution was allowed to stir at 78 C for
2 h, and then the reaction mixture was slowly warmed to rt and
stirred for additional 1 h. After completion of the reaction
(monitored by LCMS), saturated NH4Cl solution was added and
stirred for 10 min at rt. Ethyl acetate (100 mL) was added, organic
phase was extracted and washed with water (2  20 mL), brine
solution (2  20 mL) and dried over anhydrous Na2SO4. The solvent
was evaporated under reduced pressure to give the crude residue.
The crude residue was dissolved in CH3CN (60 mL) and cooled
to 0 C, PyHF (2.44 g, 24.6 mmol) was added slowly over a period
of 10 min, the resulting solution was stirred at rt for 18 h. After
completion of the reaction, it was neutralized with saturated
NaHCO3 solution and extracted with ethyl acetate (2  50 mL),
combined organic layer was washed with water (2  20 mL), brine
solution (2  20 mL) and dried over anhydrous Na2SO4. After
evaporation, the crude compound was puriﬁed by ﬂash column
chromatography on silica gel (230–400 mesh) using EtOAc/CyH
5–10% as a gradient to afford pure compound 9a (3.38 g, 68%) as
a pale yellow viscous liquid. 1H NMR (400 MHz, CDCl3): d 8.61 (d,
J = 2.3 Hz, 1H), 8.18 (d, J = 2.3 Hz, 1H), 7.54–7.48 (m, 1H), 7.42 (s,
1H), 7.19 (t, J = 7.5 Hz, 1H), 7.13–7.09 (m, 1H), 6.97 (d, J = 8.7 Hz,
2H), 6.88 (d, J = 8.5 Hz, 2H), 5.81 (s, 1H), 5.61 (s, 1H), 4.95 (s, 2H),
4.51 (q, J = 7.1 Hz, 2H), 3.94 (s, 2H), 2.97 (s, 3H), 1.53 (t,
J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3): d 159.4, 156.1, 149.4,
144.2, 136.4, 135.2, 131.4, 129.9, 128.8, 128.7, 121.3, 117.7,
113.8, 112.6, 74.7, 70.0, 61.4, 55.4, 29.9, 24.5, 14.5. HPLC-MS
(ESI) m/z calcd for C25H26NO4 [M+H]+: 404.19, found: 404.12. TLC
Rf = 0.6 (30% EtOAc/CyH).
5.5. Ethyl 5-(2-amino-4-(2-((4-methoxybenzyl)oxy)phenyl)-4,
5-dihydrooxazol-4-yl)-2-methylnicotinate (10a)
To a suspension of 9a (1.3 g, 3.22 mmol) and silver cyanate
(1.45 g, 9.67 mmol) in a mixture of CH3CN/EtOAc (2:1; 30 mL),
was added a solution of I2 (0.9 g, 3.54 mmol) in ethyl acetate
(5.0 mL) at 0 C over a period of 10 min. Then reaction mixture
was allowed to stir at rt for 45 min and the reaction was monitoredby LCMS. After complete consumption of oleﬁn, the reaction mix-
ture was ﬁltered on a celite pad and washed with ethyl acetate
and the ﬁltrate was concentrated under reduced pressure to give
crude intermediate. The residue was re-dissolved in THF and
saturated aqueous NH3 (10:1; 15 mL) was added and the mixture
was reﬂuxed at 80 C for 18 h. The reaction mixture was diluted
with ethyl acetate (15 mL) and washed with water (2  10 mL),
brine solution (1  10 mL) and organic phase was dried over anhy-
drous Na2SO4 and concentrated to yield crude product that was
puriﬁed by ﬂash column chromatography on silica gel (230–400
mesh) using MeOH/CH2Cl2 2–5% (MeOH buffered with NH3 10:1)
as a gradient to afford compound 10a (0.68 g, 46%) as a white vis-
cous liquid. 1H NMR (400 MHz, CD3OD): d 8.21 (d, J = 2.4 Hz, 1H),
7.93 (d, J = 2.4 Hz, 1H), 7.75 (d, J = 7.3 Hz, 1H), 7.35 (t, J = 7.7 Hz,
1H), 7.06 (dd, J = 8.0, 0.8 Hz, 2H), 6.88 (d, J = 8.6 Hz, 2H), 6.76 (d,
J = 8.6 Hz, 2H), 5.04 (d, J = 9.6 Hz, 1H), 4.91 (d, J = 10.8 Hz, 1H),
4.72 (d, J = 10.8 Hz, 1H), 4.38 (d, J = 9.5 Hz, 1H), 4.31 (q, J = 7.1 Hz,
2H), 3.76 (s, 3H), 2.72 (s, 3H), 1.32 (t, J = 7.1 Hz, 3H). 13C NMR
(101 MHz, CD3OD): d 166.3, 162.0, 159.8, 157.1, 154.9, 148.7,
140.7, 136.1, 132.9, 129.2, 128.5, 127.0, 125.6, 120.7, 113.5,
112.1, 79.2, 72.8, 69.7, 61.3, 54.5, 22.6, 13.3. HPLC-MS (ESI)m/z cal-
cd for C26H28N3O5 [M+H]+: 462.20, found: 462.07. TLC Rf = 0.3 (10%
MeOH/ CH2Cl2).
5.6. Ethyl 5-(2-amino-4-(2-hydroxyphenyl)-4,5-dihydrooxazol-
4-yl)-2-methylnicotinate (11)
To a solution of amino-oxazoline 10a (0.8 g, 1.73 mmol) in CH2
Cl2 (5 mL) was added CH2Cl2/TFA (1:1, 20 mL), slowly at 0 C. The
resultant solution was allowed to stir at rt for 2 h, and then solvent
was removed under reduced pressure. The residue was dissolved in
ethyl acetate (100 mL), washed with saturated NaHCO3 solution
(1  20 mL), water (2  20 mL), brine solution (1  20 mL) and
the organic phase was dried over anhydrous Na2SO4 and concen-
trated to give crude mixture that was puriﬁed by ﬂash column
chromatography on silica gel (230–400 mesh) using MeOH/CH2Cl2
5–10% (MeOH buffered with NH3 10:1) as a gradient to afford com-
pound 11 (0.53 g, 90%) as a pale yellow viscous liquid.1H NMR
(400 MHz, CD3OD): d 8.60 (d, J = 2.3 Hz, 1H), 8.39 (d, J = 2.2 Hz,
1H), 7.35 (t, J = 8.1 Hz, 2H), 7.01 (t, J = 7.6 Hz, 1H), 6.93 (d,
J = 8.0 Hz, 1H), 5.54 (d, J = 9.9 Hz, 1H), 5.34 (d, J = 9.9 Hz, 1H),
4.38 (q, J = 7.1 Hz, 2H), 2.84 (s, 3H), 1.36 (t, J = 7.1 Hz, 3H). 13C
NMR (101 MHz, CD3OD): d 165.0, 158.5, 153.9, 146.8, 138.8,
136.6, 130.9, 127.2, 125.9, 125.4, 120.4, 119.9, 116.2, 81.4, 61.9,
43.9, 21.7, 13.2. HPLC-MS (ESI) m/z calcd for C18H20N3O4 [M+H]+:
342.14, found: 342.01. TLC Rf = 0.2 (15% MeOH/ CH2Cl2).5.7. Ethyl 5-(2-methoxybenzoyl)-2-methylnicotinate (13)
To a heterogeneous solution of 4a (2.8 g, 9.81 mmol) and K2CO3
(4.06 g, 29.44 mmol) in acetone (50 mL), was added methyl iodide
(2.09 g, 14.72 mmol) dropwise and the resulting solution was
reﬂuxed for 18 h. Upon completion of reaction, the mixture was
cooled to rt and ﬁltered through celite pad, washed couple of times
with ethyl acetate (2  20 mL). The solvent was evaporated under
reduced pressure to give crude product. The crude 13 was puriﬁed
by ﬂash column chromatography on silica gel (230–400 mesh)
using EtOAc/CyH (2–5%) as a gradient to afford pure compound
13 (2.4 g, 83%) as a colourless liquid. 1H NMR (400 MHz, CDCl3):
d 8.82 (d, J = 2.2 Hz, 1H), 8.58 (d, J = 2.2 Hz, 1H), 7.53–7.47 (m,
1H), 7.44 (dt, J = 4.1, 2.1 Hz, 1H), 7.05 (tt, J = 5.3, 2.6 Hz, 1H), 6.97
(d, J = 8.4 Hz, 1H), 4.37 (q, t, J = 7.1 Hz, 2H), 3.68 (s, 3H), 2.87 (s,
3H), 1.37 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3): d 194.0,
166.2, 163.6, 157.7, 152.9, 139.1, 133.4, 131.3, 130.5, 127.5,
125.8, 121.2, 111.7, 61.8, 55.7, 25.2, 14.4. HPLC-MS (ESI) m/z calcd
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5.8. Ethyl 5-(1-(2-methoxyphenyl)vinyl)-2-methylnicotinate
(14)
To a solution of ketone 13 (1.8 g, 5.65 mmol) in THF (30 mL),
was added trimethylsilyl methyl lithium (0.79 g, 8.47 mmol;
1.0 M solution in THF) dropwise at 78 C over a period of
10 min. The resulting solution was allowed to stir at 78 C for
2 h, and then the reaction mixture was slowly warmed to rt and
stirred for additional 30 min. The reaction completion was moni-
tored by LCMS, and upon substrate consumption, saturated aq
NH4Cl solution was added and stirred for 10 min at rt. The layers
were separated, extracted couple of times with ethyl acetate
(2  30 mL), combined organic phase was washed with water
(2  20 mL), brine solution (2  20 mL) and dried over anhydrous
Na2SO4. The solvent was evaporated under reduced pressure to
give a crude residue.
The crude residue was dissolved in CH3CN (30 mL) and cooled
to 0 C, PyHF (1.84 g, 11.3 mmol) was added slowly over a period
of 15 min. The resultant solution was stirred at rt for 18 h, after
completion of the reaction, it was neutralized with saturated
NaHCO3 solution and extracted with ethyl acetate (2  30 mL),
combined organic layer was washed with water (2  20 mL), brine
solution (2  20 mL) and dried over anhydrous Na2SO4. After
evaporation, residue was puriﬁed by ﬂash column chromatography
on silica gel (230–400 mesh) using EtOAc/CyH 5–10% as a gradient
to afford pure compound 14 (1.3 g, 77%) as a pale yellow liquid. 1H
NMR (400 MHz, CDCl3): d 8.36 (d, J = 2.3 Hz, 1H), 7.98 (d, J = 2.3 Hz,
1H), 7.26–7.17 (m, 1H), 7.17–7.10 (m, 1H), 6.86 (t, J = 7.4 Hz, 1H),
6.76 (d, J = 8.3 Hz, 1H), 5.62 (s, 1H), 5.30 (s, 1H), 4.23 (q,
J = 7.1 Hz, 2H), 3.48 (s, 3H), 2.69 (s, 3H), 1.24 (t, J = 7.1 Hz, 3H).
13C NMR (101 MHz, CDCl3) d 167.0, 158.2, 157.0, 149.8, 143.9,
135.8, 134.3, 131.2, 129.9, 129.5, 125.3, 121.0, 117.4, 111.3, 61.4,
55.5, 24.7, 14.4. HPLC-MS (ESI) m/z calcd for C18H20NO3 [M+H]+:
298.14, found: 298.10. TLC Rf = 0.5 (15% EtOAc/CyH).5.9. Ethyl 5-(2-amino-4-(2-methoxyphenyl)-4,5-dihydrooxazol-
4-yl)-2-methylnicotinate (12)
To a suspension of oleﬁn 14 (0.5 g, 1.5 mmol) and silver cyanate
(0.7 g, 4.5 mmol) in a mixture of CH3CN/EtOAc (2:1; 23 mL), was
added a solution of I2 (1.1 equiv) in ethyl acetate (3.0 mL) at 0 C
over a period of 10 min. The resulting mixture was allowed to stir
at rt for 1 h and the reaction completion was monitored by LCMS.
After complete consumption of oleﬁn, it was ﬁltered on a celite
pad, washed with ethyl acetate (2  20 mL) and the ﬁltrate was
concentrated under reduced pressure to give crude residue. The
residue was re-dissolved in THF (15 mL) and saturated aqueous
NH3 (1.5 mL) was added, the resulting solution was reﬂuxed at
80 C for 18 h. After cooling to rt, the reaction mixture was diluted
with ethyl acetate (25 mL), washed with water (2  10 mL), brine
solution (1  10 mL) and the organic phase was dried over anhy-
drous Na2SO4 and concentrated to give crude product mixture that
was puriﬁed by ﬂash column chromatography on silica gel (230–
400 mesh) using MeOH/CH2Cl2 2–5% (MeOH buffered with NH3
10:1) as a gradient to afford compound 12 (0.38 g, 66%) as a colour-
less viscous liquid. 1H NMR (400 MHz, CD3OD): d 8.27 (d, J = 2.4 Hz,
1H), 8.00 (d, J = 2.4 Hz, 1H), 7.65 (d, J = 7.7 Hz, 1H), 7.37–7.19 (m,
1H), 7.03–6.85 (m, 2H), 5.10 (d, J = 9.4 Hz, 1H), 4.38 (d, J = 9.4 Hz,
1H), 4.26 (q, J = 7.1 Hz, 2H), 3.60 (d, J = 7.9 Hz, 3H), 2.65 (s, 3H),
1.27 (t, J = 7.5, 3H). 13C NMR (101 MHz, CD3OD): d 166.4, 162.2,
157.1, 155.8, 148.7, 140.7, 136.5, 132.7, 129.3, 127.1, 125.6,
120.7, 111.2, 79.5, 73.0, 61.4, 54.5, 22.6, 13.3. HPLC-MS (ESI) m/zcalcd for C19H22N3O4 [M+H]+: 356.16, found: 356.04. TLC Rf = 0.3
(10% MeOH/CH2Cl2).
5.10. 5-(2-amino-4-(2-methoxyphenyl)-4,5-dihydrooxazol-4-
yl)-N,N-diethyl-2-methylnicotinamide (15)
To compound 12 (50 mg, 0.13 mmol) was added THF/MeOH
(2.5 mL; 3:1) followed by LiOH (6 mg, 0.27 mmol). The reaction
mixture was heated at 60 C and stirred at the same temperature
for 18 h. The reaction mixture was cooled to rt, ﬁltered and solvent
was removed under reduced pressure. The crude acid was then
taken for next step without further puriﬁcation. HPLC-MS (ESI)
m/z calcd for C17H18N3O4 [M+H]+: 328.13, found: 328.03; TLC
Rf = 0.2 (20% MeOH/CH2Cl2).
The acid was dissolved in DMF (3 mL) to which was added
DIPEA (0.02 g, 0.26 mmol), HATU (0.08 g, 0.39 mmol) and diethyl
amine (0.1 g, 0.52 mmol), and the resulting solution was stirred
at 50 C for 4 h. Then the reaction mixture was cooled to rt and
water (10 mL) was added and the mixture was extracted with ethyl
acetate (3  15 mL). The combined organic extracts were washed
with water (3  10 mL), brine solution (1  10 mL) dried over
anhydrous Na2SO4 and concentrated to give crude product that
was puriﬁed by column chromatography on silica gel (230–400
mesh) using 5–10% MeOH/CH2Cl2 (MeOH buffered with NH3
10:1) as a gradient to give pure compound 15 (27 mg, 63%) as a
colourless viscous liquid. 1H NMR (400 MHz, CD3OD): d 8.27 (s,
1H), 7.69 (d, J = 7.4 Hz, 1H), 7.40–7.33 (m, 2H), 7.03 (dd, J = 14.9,
7.8 Hz, 2H), 5.23 (d, J = 9.4 Hz, 1H), 4.49 (d, J = 9.7 Hz, 1H), 3.66
(s, 3H), 3.31 (d, J = 1.3 Hz, 2H), 3.09 (s, 2H), 2.42 (s, 3H), 1.23 (t,
J = 7.1 Hz, 3H), 0.96 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CD3OD):
d 170.0, 155.8, 152.2, 146.6, 142.9, 131.9, 129.4, 127.0, 120.7,
120.4, 111.2, 79.7, 54.5, 43.9, 43.3, 39.6, 20.0, 13.0, 11.7. HPLC-
MS (ESI) m/z calcd for C21H27N4O3 [M+H]+: 383.21, found:
383.12. TLC Rf = 0.2 (15% MeOH/CH2Cl2).
5.11. Methyl 7-((tert-butyldimethylsilyl)oxy)-3-oxo-2-
((4-oxo-4H-chromen-3-yl)methylene)heptanoate (19a)
A mixture of 3-formyl-chromone (1.25 g, 6.96 mmol), methyl
7-((tert-butyldimethylsilyl)oxy)-3-oxoheptanoate (2.11 g, 6.96
mmol), and sodium acetate (0.57 g, 6.96 mmol) in acetic anhydride
(21 mL) was heated at 125 C for 4 h. The acetic anhydride was
removed under reduced pressure, the residue was re-dissolved in
ethyl acetate (50 mL) and washed with water (2  15 mL), brine
solution (1  15 mL) and organic phase was dried over anhydrous
Na2SO4 and concentrated to yield crude product. The crude com-
pound was puriﬁed by ﬂash column chromatography on silica gel
(230400 mesh) using 30% EtOAc/CyH to afford pure compound
19b (2.15 g, 69%) (2:1 mixture of cis/trans isomer) as pale yellow
viscous liquid. 1H NMR (400 MHz, CDCl3): d 8.30 (d, J = 0.9 Hz,
1H), 8.24 (td, J = 7.9, 1.2 Hz, 2H), 7.75–7.67 (m, 2H), 7.62 (d,
J = 0.9 Hz, 1H), 7.49–7.43 (m, 3H), 3.86–3.81 (m, 4H), 3.64 (t,
J = 6.3 Hz, 2H), 3.58 (t, J = 6.4 Hz, 1H), 2.81 (t, J = 7.3 Hz, 2H), 2.73
(t, J = 7.4 Hz, 1H), 1.78–1.65 (m, 4H), 1.61–1.47 (m, 3H), 0.89 (s,
9H), 0.85 (s, 5H), 0.06(s, 6H), 0.00 (s, 3H). 13C NMR
(101 MHz,CDCl3): d 197.4, 167.7, 165.1, 156.8, 156.1, 135.8,
134.5, 134.5, 132.1, 131.6, 126.6, 126.5, 126.3, 126.1, 123.9,
119.4, 118.4, 63.1, 62.9, 52.8, 38.9, 32.4, 32.3, 26.2, 26.1, 20.7,
20.3, 18.6, 5.1, 5.1. TLC Rf = 0.4 (30% EtOAc/CyH).
5.12. Methyl 6-(2-hydroxybenzoyl)chroman-8-carboxylate (20a)
To a solution of 19b (2.1 g, 4.58 mmol) in MeOH (9.2 mL), was
added PPTS (9.3 g, 36.6 mmol) and the resulting solution was
reﬂuxed at 90 C for 18 h. Upon reaction completion (tlc),
MeOH was removed under reduced pressure. The residue was
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(2  20 mL), brine solution (1  20 mL) and the organic phase
was dried over anhydrous Na2SO4 and concentrated to give crude
product. The crude product was then puriﬁed by ﬂash column
chromatography on silica gel (230–400 mesh) using ethyl acet-
ate/cyclohexane 5–10% as a gradient to afford pure compound
20b (0.96 g, 67%) as a colourless viscous liquid. 1H NMR
(400 MHz, CDCl3): d 11.9 (s, 1H), 8.00 (d, J = 2.3 Hz, 1H), 7.63–
7.59 (m, 2H), 7.54–7.48 (m, 1H), 7.07 (d, J = 8.4 Hz, 1H), 6.91 (t,
J = 7.6 Hz, 1H), 4.42–4.37 (m, 2H), 3.88 (s, 3H), 2.90 (t, J = 6.5 Hz,
2H), 2.13–2.06 (m, 2H). 13C NMR (101 MHz, CDCl3) d 199.6,
166.0, 163.2, 158.4, 136.3, 135.1, 133.3, 131.9, 129.1, 124.1,
119.4, 119.3, 118.9, 118.7, 67.9, 52.4, 25.5, 21.6. HPLC-MS (ESI)
m/z calcd for C18H17O5 [M+H]+: 313.11, found: 313.23. TLC
Rf = 0.4 (30% EtOAc/CyH).
5.13. Methyl 6-(2-methoxy-5-methylbenzoyl)chroman-8-
carboxylate (21a)
To a heterogeneous solution of 20a (0.80 g, 2.48 mmol) and
K2CO3 (1.03 g, 7.45 mmol) in acetone (15 mL), was added methyl
iodide (0.52 mL, 3.72 mmol) at rt, the resulting solution was
reﬂuxed for 6 h. Then the reaction mixture was ﬁltered, washed
several times with ethyl acetate (2  20 mL) and the ﬁltrate was
concentrated under reduced pressure to give crude product. The
crude was puriﬁed by column chromatography on silica gel
(230–400 mesh) using EtOAc/CyH (5–10%) as a gradient to afford
pure compound 21a (0.63 g, 78%) as a colourless liquid. 1H NMR
(400 MHz, CDCl3): d 8.01 (d, J = 2.3 Hz, 1H), 7.75–7.72 (m, 1H),
7.46 (ddd, J = 8.5, 7.5, 1.7 Hz, 1H), 7.33 (dd, J = 7.5, 1.7 Hz, 1H),
7.04 (td, J = 7.4, 0.7 Hz, 1H), 6.99 (d, J = 8.3 Hz, 1H), 4.39–4.33 (m,
2H), 3.84 (s, 3H), 3.74 (s, 3H), 2.84 (t, J = 6.5 Hz, 2H), 2.10–2.01
(m, 2H). 13C NMR (101 MHz, CDCl3): d 194.7, 166.3, 158.9, 157.4,
135.2, 132.6, 132.0, 129.7, 129.4, 128.9, 123.6, 120.8, 119.4,
111.8, 67.9, 55.9, 52.3, 25.4, 21.6. HPLC-MS (ESI) m/z calcd for
C19H19O5 [M+H]+: 327.12, found: 327.02. TLC Rf = 0.5 (30% EtOAc/
CyH).
5.14. Methyl 6-(2-amino-4-(2-methoxy-5-methylphenyl)-4,5-
dihydrooxazol-4-yl)chroman-8-carboxylate (23a)
To a suspension of 22a (0.3 g, 0.88 mmol), silver cyanate (0.39 g,
2.63 mmol) in a mixture of CH3CN/EtOAc (2:1; 6 mL), was added a
solution of I2 (0.27 g, 1.01 mmol) in ethyl acetate (1.5 mL) at 0 C
over a period of 10 min, the reaction was allowed to stir at rt for
2 h. The reaction was monitored by LCMS, upon substrate (22a)
consumption; the reaction mixture was ﬁltered on a celite pad
and concentrated under reduced pressure. The residue was re-dis-
solved in THF and saturated aq NH3 (10:1; 5 mL) and heated at
80 C for 18 h. The reaction mixture was diluted with ethyl acetate
(50 mL) and washed with water (2  10 mL), brine solution
(1  10 mL) and the organic phase was dried over anhydrous Na2
SO4 and concentrated to afford crude product that was then puri-
ﬁed by ﬂash column chromatography on silica gel (230–400 mesh)
using MeOH/CH2Cl2 (2–5%; MeOH buffered with NH3 10:1) as a
gradient to afford compound 23a (0.2 g, 57%) as a colourless vis-
cous liquid. 1H NMR (400 MHz, CD3OD): d 7.50 (dd, J = 8.3,
1.2 Hz, 1H), 7.39–7.34 (m, 2H), 7.07–7.00 (m, 3H), 5.25 (d,
J = 9.4 Hz, 1H), 4.75 (d, J = 9.4 Hz, 1H), 4.22–4.18 (m, 2H),
3.79–3.76 (m, 3H), 3.68 (s, 3H), 2.74 (t, J = 6.4 Hz, 2H), 1.99–1.92
(m, 2H). 13C NMR (101 MHz, CD3OD): d 167.3, 162.0, 156.2,
154.1, 135.6, 131.5, 129.6, 126.7, 126.5, 123.9, 120.6, 120.4,
118.7, 111.7, 81.1, 71.8, 66.9, 54.7, 51.3, 25.1, 21.6. HPLC-MS
(ESI) m/z calcd for C21H23N2O5 [M+H]+: 383.16, found: 383.01.
TLC Rf = 0.2 (15% MeOH/CH2Cl2).5.15. Methyl 7-((tert-butyldimethylsilyl)oxy)-2-((6-methyl-4-
oxo-4H-chromen-3-yl)methylene)-3-oxoheptanoate (19b)
A mixture of 6-methyl 3-formyl chromone (1.5 g, 7.73 mmol),
methyl 7-((tert-butyldimethylsilyl)oxy)-3-oxoheptanoate (2.29 g,
7.73 mmol), and sodium acetate (0.64 g, 7.73 mmol) in acetic
anhydride (24 mL) was heated at 125 C for 4 h. Upon reaction
completion acetic anhydride was removed under reduced pressure,
and the residue was dissolved in ethyl acetate (50 mL) washed
with water (2  15 mL), brine solution (1  15 mL) and dried over
anhydrous Na2SO4 concentrated to give crude product. The crude
was puriﬁed by ﬂash column chromatography on silica gel (230–
400 mesh) using 10–15% EtOAc/CyH to afford pure compound
19b (2.6 g, 73%) as a pale yellow liquid (1:1 mixture of cis/trans iso-
mer). 1H NMR (400 MHz, CDCl3): d 8.27 (d, J = 0.9 Hz, 1H), 8.21
(s, 1H), 8.02–7.95 (m, 2H), 7.65 (d, J = 1.0 Hz, 1H), 7.61 (d,
J = 0.9 Hz, 1H), 7.53–7.45 (m, 2H), 7.35 (dd, J = 8.5, 6.5 Hz, 2H),
3.84 (s, 3H), 3.83 (s, 3H), 3.66–3.61 (m, 2H), 3.58 (t, J = 6.4 Hz,
2H), 2.80 (t, J = 7.3 Hz, 2H), 2.73 (t, J = 7.4 Hz, 2H), 2.44 (d,
J = 4.1 Hz, 6H), 1.79–1.64 (m, 4H), 1.61–1.46 (m, 4H), 0.87 (s, 9H),
0.83 (s, 9H), 0.07 (s, 6H), 0.02 (s, 6H). 13C NMR (101 MHz, CDC3):
d 197.3, 175.3, 175.2, 167.6, 165.0, 156.7, 154.3, 154.3, 136.3,
136.1, 135.6, 135.6, 132.1, 131.7, 125.7, 125.7, 123.4, 119.0,
118.9, 118.1, 118.1, 62.9, 62.9, 52.6, 52.5, 43.0, 38.7, 32.3, 32.2,
26.1, 26.0, 21.1, 21.0, 20.6, 20.2, 18.4, 18.4, 5.2, 5.2. TLC
Rf = 0.5 (30% EtOAc/CyH).
5.16. Methyl 6-(2-hydroxybenzoyl)chroman-8-carboxylate
(20b)
To a solution of 19b (2.1 g, 4.58 mmol) in MeOH (9.2 mL), was
added PPTS (9.3 g, 36.6 mmol) at rt, the resulting solution was
reﬂuxed at 90 C for 18 h. After all the starting material was con-
sumed, the reaction mixture was cooled to rt and MeOH was
removed under reduced pressure. The residue was re-dissolved
in ethyl acetate (50 mL) washed with water (2  15 mL), brine
solution (2  15 mL) and dried over anhydrous Na2SO4 concentrat-
ed to give a crude product mixture that was then puriﬁed by ﬂash
column chromatography on silica gel (230–400 mesh) using
EtOAc/CyH 15–20% as a gradient to afford pure compound 20b
(0.96 g, 67%) as a colourless viscous liquid. 1H NMR (400 MHz,
CDCl3): d 11.62 (s, 1H), 7.97 (s, 1H), 7.56 (s, 1H), 7.34 (s, 1H),
7.28 (dd, J = 8.4, 2.4 Hz, 1H), 6.93 (d, J = 8.4 Hz, 1H), 4.40–4.34 (m,
2H), 3.88–3.85 (m, 3H), 2.87 (t, J = 6.4 Hz, 2H), 2.25 (s, 3H),
2.14–1.98 (m, 2H). 13C NMR (101 MHz, CDCl3): d 199.5, 166.0,
161.0, 158.3, 137.3, 135.0, 132.9, 131.8, 129.2, 128.0, 124.1,
119.3, 119.1, 118.3, 67.9, 52.4, 27.1, 25.5, 21.6. HPLC-MS (ESI) m/
z calcd for C19H19O5 [M+H]+: 327.12, found: 326.96. TLC Rf = 0.3
(30% EtOAc/CyH).
5.17. Methyl 6-(2-methoxy-5-methylbenzoyl)chroman-
8-carboxylate (21b)
To a heterogeneous solution of 20b (1.1 g, 3.20 mmol) and
K2CO3 (1.3 g, 9.80 mmol) in acetone (17 mL), was added methyl
iodide (0.31 mL, 4.9 mmol) at rt, and the resulting mixture was
reﬂuxed for 18 h. Then the reaction mixture was ﬁltered on celite
pad, washed several times with ethyl acetate (2  10 mL) and con-
centrated under reduced pressure to give a crude product mixture
that was puriﬁed by ﬂash column chromatography on silica gel
(230–400 mesh) using EtOAc/CyH (10–15%) as a gradient to afford
pure compound 21b (0.89 g, 80%) as a pale yellow liquid. 1H NMR
(400 MHz, CDCl3): d 8.00 (d, J = 2.3 Hz, 1H), 7.72 (dd, J = 2.2, 1.0 Hz,
1H), 7.29–7.17 (m, 1H), 7.15–7.05 (m, 1H), 6.87 (d, J = 8.4 Hz, 1H),
4.54–4.20 (m, 2H), 3.83 (s, 3H), 3.68 (s, 3H), 2.83 (t, J = 6.5 Hz, 2H),
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166.4, 158.9, 155.3, 135.2, 132.6, 132.4, 130.3, 130.0, 129.4, 128.7,
123.6, 119.4, 111.8, 67.9, 56.0, 52.3, 27.1, 25.4, 21.6. HPLC-MS (ESI)
m/z calcd for C20H21O5 [M+H]+: 341.14, found: 341.01. TLC Rf = 0.4
(30% EtOAc /CyH).
5.18. Methyl 6-(1-(2-methoxy-5-methylphenyl)vinyl)chroman-
8-carboxylate (22b)
To a solution of ketone 21b (0.8 g, 2.27 mmol) in THF (15 mL),
was added trimethylsilyl methyl lithium (3.41 mL, 3.42 mmol)
dropwise at 78 C over a period of 10 min, the resulting mixture
was allowed to stir at 78 C for 2 h. Then the reaction mixture
was slowly warmed to rt and stirred for additional 1 h. The reac-
tion was monitored by LCMS. After completion of reaction, a
saturated aqueous NH4Cl solution (5 mL) was added to the reaction
mixture and extracted with ethyl acetate (2  25 mL). The com-
bined organic layer was washed with water (2  15 mL), brine
solution (1  15 mL) and dried over anhydrous Na2SO4 and con-
centrated to give crude product.
The crude product was dissolved in CH3CN (15 mL) and PyHF
(0.319 mL, 4.55 mmol) was added at 0 C over a period of 5 min,
the resulting solution was stirred at rt for 18 h. The reaction mix-
ture was quenched by the addition of saturated aqueous NaHCO3
and the reaction mixture was extracted with ethyl acetate
(2  25 mL). The combined extracts were washed with water
(2  15 mL), brine solution (1  15 mL) dried over anhydrous Na2
SO4 and concentrated to give crude product that was puriﬁed by
ﬂash column chromatography on silica gel (230–400 mesh) using
EtOAc/CyH 10–15 % as a gradient to afford pure compound 22b
(0.47 g, 61%) as a pale yellow liquid. 1H NMR (400 MHz, CD2Cl2):
d 7.36 (d, J = 2.1 Hz, 1H), 7.14–7.01 (m, 2H), 6.95 (d, J = 2.0 Hz,
1H), 6.76 (d, J = 8.3 Hz, 1H), 5.53 (s, 1H), 5.10 (s, 1H), 4.21–4.10
(m, 2H), 3.72 (m, 3H), 3.55 (s, 3H), 2.69 (t, J = 6.6 Hz, 2H), 2.24 (s,
3H), 2.01–1.83 (m, 2H). 13C NMR (101 MHz, CD2Cl2) d 166.9,
155.2, 154.1, 146.4, 132.5, 131.9, 131.6, 130.7, 130.1, 129.5,
127.1, 123.4, 119.5, 114.0, 111.5, 67.2, 55.9, 51.9, 25.4, 22.1, 20.3.
HPLC-MS (ESI) m/z calcd for C21H23O4 [M+H]+: 339.16, found:
339.02. TLC Rf = 0.5 (20% EtOAc/CyH).
5.19. Methyl 6-(2-amino-4-(2-methoxy-5-methylphenyl)-4,
5-dihydrooxazol-4-yl)chroman-8-carboxylate (23b)
To a suspension of 22b (0.3 g, 0.84 mmol) and silver cyanate
(0.37 g, 2.52 mmol) in a mixture of CH3CN/EtOAc (2:1; 6 mL),
was added a solution of I2 (0.26 g, 1.01 mmol) in ethyl acetate
(1.5 mL) at 0 C over a period of 10 min. The resulting reaction mix-
ture was allowed to stir at rt for 1 h. The reaction was monitored by
LCMS, and after completion of reaction it was ﬁltered on a celite
pad and concentrated under reduced pressure. The residue was
re-dissolved in THF (6 mL) and saturated aqueous NH3 (0.6 mL)
was added at rt, the resulting solution was reﬂuxed at 80 C for
18 h. The reaction mixture was diluted with ethyl acetate
(50 mL) and washed with water (2  10 mL), brine solution
(1  10 mL) dried over anhydrous Na2SO4 and concentrated to give
crude product. The crude compound was puriﬁed by ﬂash column
chromatography on silica gel (230–400 mesh) using MeOH/CH2Cl2
(2–5%; MeOH buffered with NH3 10:1) as a gradient to afford com-
pound 23b (0.2 g, 57%) as a colourless viscous liquid. 1H NMR
(400 MHz, CD3OD): d 7.44 (s, 1H), 7.34 (d, J = 2.6 Hz, 1H), 7.11 (d,
J = 8.2 Hz, 1H), 7.00 (d, J = 2.2 Hz, 1H), 6.87 (d, J = 8.3 Hz, 1H),
5.10 (d, J = 9.2 Hz, 1H), 4.47 (d, J = 9.3 Hz, 1H), 4.23–4.14 (m, 2H),
3.77 (s, 3H), 3.61 (s, 3H), 2.72 (t, J = 6.3 Hz, 2H), 2.31 (s, 3H),
2.01–1.88 (m, 2H). 13C NMR (101 MHz, CD3OD): d 167.5, 161.6,
154.0, 153.7, 137.7, 133.2, 131.7, 129.8, 129.0, 127.7, 126.6,
123.4, 118.4, 111.3, 80.4, 73.5, 66.8, 54.6, 51.2, 43.9, 25.1, 21.7.HPLC-MS (ESI) m/z calcd for C22H25N2O5 [M+H]+: 397.18, found:
396.99. TLC Rf = 0.2 (15% MeOH/CH2Cl2).
5.2. Wittig oleﬁnation
5.2.1. General procedure (22a–g)
To a solution of methyltriphenylphosphonium bromide
(1.6 equiv) in dry THF (100 mL), KOtBu (1.75 equiv in 75 mL dry
THF) was added dropwise at 0 C under a N2 atmosphere and stir-
red for 2 h at 0 C. The respective ketone 7a–g (5.0 g, 1 equiv) in dry
THF (50 mL) was added dropwise at 0 C and reﬂuxed for 5 h. After
completion of the reaction, water (150 mL) was added and the
reaction mixture was extracted with EtOAc (3  200 mL). The
organic phase was washed with saturated aq NaHCO3 (100 mL),
brine (100 mL), dried over MgSO4 and the solvent was removed
under reduced pressure. The products were puriﬁed by column
chromatography (Grace Reveleris apparatus) on silica gel (230–
400 mesh) using 0–50% EtOAc/hexane as a gradient.
5.3. General procedure for the preparation ﬁnal compounds
(24a–24h)
Reactions were performed in parallel in a 15 mL reaction tube in
a 24 position Mettler-Toledo Miniblock equipped with a heat
transfer block and inert gas manifold. The carboxylic acid lithium
salt produced from the corresponding methyl ester (0.075 mmol,
0.5 mL as a 0.15 M solution in DMF) was transferred in the reaction
tube together with EDCHCl (0.15 mmol, 28 mg, 2 equiv), DIPEA
(0.375 mmol, 62 ll, 5 equiv) and HOBt (0.15 mmol, 0.3 mL of as a
0.5 M solution in dry DMF, 2 equiv). The Mettler block was closed
and charged under N2, and the corresponding amine (0.225 mmol
as a solution in 1 mL dry DMF, 3 equiv) was added and the reaction
was stirred at 50 C overnight. Solvent was evaporated in a cen-
trifugal evaporator and the residue was re-dissolved in MeOH
(1.0 mL). The crude methanolic solution was transferred to a 96
position ﬁltration plate and centrifuged into a 96 deep-well plate
for uHPLC/MS analysis and HPLC puriﬁcation.5.3.1. 6-[2-Amino-4-(2-ethoxy-5-methylphenyl)-4,5-dihydro-
1,3-oxazol-4-yl]-N-(oxan-4-ylmethyl)-3,4-dihydro-2H-1-
benzopyran-8-carboxamide (24a)
Synthesized from compound 23e and 4-aminomethyltetrahy-
dropyrane. 1H NMR (300 MHz, CDCl3): d 8.50 (s, 1H), 8.09 (d,
J = 2.7 Hz, 1H), 8.03 (t, J = 5.9 Hz, 1H), 7.36 (d, J = 1.8 Hz, 1H), 7.08
(dd, J = 1.5, 8.2 Hz, 1H), 7.02 (d, J = 2.7 Hz, 1H), 6.73 (d, J = 8.3 Hz,
1H), 5.54 (d, J = 9.5 Hz, 1H), 4.89 (d, J = 9.5 Hz, 1H), 4.34–4.24 (m,
2H), 4.03–3.93 (m, 3H), 3.90–3.79 (m, 1H), 3.44–3.25 (m, 4H),
2.86–2.67 (m, 2H), 2.33 (s, 3H), 2.05–1.95 (m, 2H), 1.93–1.79 (m,
1H), 1.66 (dd, , J = 1.7, 12.7 Hz, 1H), 1.39 (dt, J = 4.3, 12.3 Hz, 2H),
1.27 (t, J = 7.0 Hz, 3H). HRMS (ESI-MS) calcd for C28H36N3O5
[M+H]+: 494.2649, found: 494.2643.
5.3.2. 6-[2-Amino-4-(2-ethoxy-5-methylphenyl)-4,
5-dihydro-1,3-oxazol-4-yl]-N-(oxan-4-yl)-3,
4-dihydro-2H-1-benzopyran-8-carboxamide (24b)
Synthesized from compound 23e and 4-aminotetrahydropy-
rane. 1H NMR (300 MHz, CDCl3): d 8.51 (s, 1H), 8.08 (d, J = 2.7 Hz,
1H), 7.93 (d, J = 7.6 Hz, 1H), 7.35 (d, J = 1.7 Hz, 1H), 7.08 (dd,
J = 1.5 Hz, J = 8.3 Hz, 1H), 7.02 (d, J = 2.7 Hz, 1H), 4.89 (d,
J = 9.5 Hz, 1H), 4.34–4.26 (m, 2H), 4,24–4.12 (m, 1H), 4.03–3.90
(m, 3H), 3.89–3.79 (m, 1H), 3.55 (dt, J = 2.3 Hz, J = 11.6 Hz, 2H),
2.86–2.68 (m, 2H), 2.33 (s, 3H), 2.05–1.95 (m, 4H), 1.56 (dq,
J = 4.3 Hz, J = 10.8 Hz, 2H), 1.27 (t, J = 7.0 Hz, 3H); LRMS (ESI) m/z:
479; HRMS (ESI-MS) calcd for C27H34N3O5 [M+H]+: 480.2493,
found: 480.2489.
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5-dihydro-1,3-oxazol-4-yl]-N-(2,2-diﬂuoroethyl)-3,
4-dihydro-2H-1-benzopyran-8-carboxamide (24c)
Synthesized from compound 23e and 2,2-diﬂuoroethylamine.
1H NMR (300 MHz, CDCl3): d 8.48 (s, 1H), 8.24 (t, J = 5.9 Hz, 1H),
8.08 (d, J = 2.7 Hz, 1H), 7.35 (d, J = 1.7 Hz, 1H), 7.09 (dd, J = 1.4,
8.4 Hz, 1H), 7.06 (d, J = 2.8 Hz, 1H), 6.74 (d, J = 8.3 Hz, 1H), 6.14
(t, J = 4.2 Hz, 1H), 5.95 (t, J = 4.2 Hz, 1H), 5.76 (t, J = 4.2 Hz, 1H),
5.51 (d, J = 9.5 Hz, 1H), 4.90 (d, J = 9.6 Hz, 1H), 4.37–4.28 (m, 2H),
4.03–3.92 (m, 1H), 3.90–3.73 (m, 3H), 2.87– 2.67 (m, 2H), 2.33 (s,
3H), 2.05–1.95 (m, 2H), 1.27 (t, J = 7.0 Hz, 3H). LRMS (ESI) m/z:
459; HRMS (ESI-MS) calcd for C24H28F2N3O4 [M+H]+: 460.2042,
found: 460.2037.
5.3.4. 6-[2-Amino-4-(2-ethoxy-5-methylphenyl)-4,5-dihydro-
1,3-oxazol-4-yl]-N-(2-ethoxyethyl)-3,4-dihydro-2H-1-benzopy-
ran-8-carboxamide (24d)
Synthesized from compound 23e and 2-ethoxyethylamine. 1H
NMR (300 MHz, CDCl3): d 8.48 (s, 1H), 8.37– 8.30 (m, 1H), 8.10
(d, J = 2.7 Hz, 1H), 7.34 (d, J = 1.9 Hz, 1H), 7.08 (dd, J = 1.4, 8.2 Hz,
1H), 7.02 (d, J = 2.7 Hz, 1H), 6.74 (d, J = 8.3 Hz, 1H), 5.53 (d,
J = 9.5 Hz, 1H), 4.91 (d, J = 9.5 Hz, 1H), 4.34–4.26 (m, 2H), 4.01–
3.91 (m, 1H), 3.90–3.80 (m, 1H), 3.65–3.55 (m, 4H), 3.54 (q,
J = 7.0 Hz, 2H), 2.83–2.66 (m, 2H), 2.33 (s, 3H), 2.04–1.94 (m, 2H),
1.27 (t, J = 7.0 Hz, 3H), 1.22 (t, J = 7.0 Hz, 3H). LRMS (ESI) m/z:
542; HRMS (ESI-MS) calcd for C27H35N4O6S [M+H]+: 543.2272,
found: 543.2270.
5.3.5. 6-[2-Amino-4-(2-ethoxy-5-methylphenyl)-4,5-dihydro-
1,3-oxazol-4-yl]-N-(pyridin-3-ylmethyl)-3,4-dihydro-2H-1-
benzopyran-8-carboxamide (24e)
Synthesized from compound 23e and 3-(aminomethyl)pyridine.
1H NMR (300 MHz, CDCl3): d 8.60 (d, J = 1.9 Hz, 1H), 8.51 (dd, ,
J = 1.6, 4.9 Hz, 1H), 8.49 (s, 1H), 8.37 (t, J = 5.8 Hz, 1H), 8.12 (d,
J = 2.7 Hz, 1H), 7.74–7.69 (m, 1H), 7.37 (d, J = 1.9 Hz, 1H), 7.31–
7.27 (m, 1H), 7.08 (dd, J = 1.6, 8.3 Hz, 1H), 7.03 (d, J = 2.6 Hz, 1H),
6.73 (d, J = 8.3 Hz, 1H), 5.52 (d, J = 9.5 Hz, 1H), 4.86 (d, J = 9.6 Hz,
1H), 4.67 (d, J = 5.9 Hz, 2H), 4.32–4.22 (m, 2H), 4.01–3.90 (m,
1H), 3.89–3.80 (m, 1H), 2.85–2.65 (m, 2H), 2.33 (s, 3H), 2.03–1.93
(m, 2H), 1.26 (t, J = 7.0 Hz, 3H). LRMS (ESI) m/z: 486; HRMS (ESI-
MS) calcd for C28H31N4O4 [M+H]+: 487.2340, found: 487.2341.
5.3.6. 4-{8-[4-(Ethanesulfonyl)piperazine-1-carbonyl]-3,
4-dihydro-2H-1-benzopyran-6-yl}-4-(2-methoxy-5-
methylphenyl)-4,5-dihydro-1,3-oxazol-2-amine (24f)
Synthesized from compound 23d and 1-(ethylsulfonyl)piper-
azine. 1H NMR (300 MHz, CDCl3): d 8.47 (s, 1H), 7.32 (s, 1H),
7.17–7.07 (m, 2H), 6.80 (t, J = 7.9 Hz, 1H), 6.70 (dd, J = 1.4,
11.2 Hz, 1H), 5.29 (dd, J = 9.5, 3.4, Hz, 1H), 4.87 (dd, , J = 9.4,
14.1 Hz, 1H), 4.21–4.11 (m, 2H), 3.84–3.75 (m, 1H), 3.71–3.64 (m,
3H), 3.48 (s, 3H), 3.40–3.25 (m, 4H), 3.04–2.90 (m, 2H), 2.81 (t,
J = 6.1 Hz, 1H), 2.65 (t, J = 6.1 Hz, 1H), 2.34 (s, 3H), 2.05–1.85 (m,
2H), 1.42–1.30 (m, 3H). LRMS (ESI) m/z: 542; HRMS (ESI-MS) calcd
for C27H35N4O6S [M+H]+: 543.2199, found: 543.2200.
5.3.7. 6-[2-Amino-4-(5-ﬂuoro-2-methoxyphenyl)-4,5-dihydro-
1,3-ox-azol-4-yl]-N-cyclohexyl-3,4-dihydro-2H-1-benzopyran-
8-carboxamide (24g)
Synthesized from compound 23g and cyclohexylamine. 1H NMR
(300 MHz, CDCl3): d 8.53 (s, 1H), 8.04 (d, J = 2.7 Hz, 1H), 7.88 (d,
J = 7.9 Hz, 1H), 7.36 (dd, J = 3.0 Hz, J = 9.2 Hz, 1H), 6.95–7.04 (m,
2H), 6.81 (dd, J = 4.3 Hz, J = 9.0 Hz, 1H), 5.43 (d, J = 9.5 Hz, 1H),
4.83 (d, J = 9.5 Hz, 1H), 4.30 (dt, J = 1.5 Hz, J = 5.4 Hz, 2H), 4.05–
3.90 (m, 1H), 3.70 (s, 3H), 2.77 (q, J = 6.3 Hz, 2H), 2.05–1.90 (m,
4H), 1.75–1.63 (m, 2H), 1.50–1.35 (m, 2H), 1.35–1.20 (m, 4H);LRMS (ESI) m/z: 467; HRMS (ESI-MS) calcd for C26H31FN4O3
[M+H]+: 468.2220, found: 468.2221.
5.3.8. 6-[2-Amino-4-(2-ethoxy-5-methylphenyl)-4,5-dihydro-
1,3-oxa-zol-4-yl]-N-(prop-2-yn-1-yl)-3,4-dihydro-2H-1-
benzopyran-8-carboxamide (24h)
Synthesized from compound 23e and 2-propynylamine. 1H
NMR (300 MHz, CDCl3): d 8.56 (s, 1H), 8.17 (t, J = 5.0 Hz, 1H),
8.11 (d, J = 2.7 Hz, 1H), 7.36 (d, J = 1.9 Hz, 1H), 7.11–7.02 (m, 2H),
6.73 (d, J = 8.3 Hz, 1H), 5.51 (d, J = 9.5 Hz, 1H), 4.87 (d, J = 9.6 Hz,
1H), 4.3–4.27 (m, 2H), 4.23 (dd, J = 2.5, 5.2 Hz, 2H), 4.02–3.79 (m,
2H), 2.86–2.66 (m, 2H), 2.33 (s, 3H), 2.25 (t, J = 2.5 Hz, 1H), 2.05–
1.95 (m, 2H), 1.27 (t, J = 7.0 Hz, 3H). LRMS (ESI) m/z: 433; HRMS
(ESI-MS) calcd for C25H28N3O4 [M+H]+: 434.2074, found: 434.2079.
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